GleamWall
中文EN

DBVT DBV Technologies S.A.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1613780 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-31.5%
TTM net income YoY-65.6%
TTM EPS YoY42.3%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,418.8%
Net margin-5,392.2%
FCF margin-4,986.9%
EBITDA margin—

Returns

ROE-205.8%
ROA-127.2%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue87.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.60M$700,000$900,000$645,000$2.80M$1.50M$800,000$511,000
R&D expense$47.00M$31.20M$33.40M$32.89M$28.60M$33.70M$21.50M$18.90M
SG&A expense$14.00M$14.60M$10.50M$11.44M$7.30M$8.50M$5.60M$5.07M
Operating income-$64.80M-$50.60M-$47.90M-$45.05M-$34.30M-$41.10M-$26.60M-$23.86M
Pretax income-$64.20M-$50.20M-$47.40M-$44.46M-$33.20M-$41.80M-$27.10M-$23.01M
Income tax$300,000$200,000$200,000$374,000$0$100,000$0$7,000
Net income-$64.50M-$50.40M-$47.60M-$44.83M-$33.20M-$41.90M-$27.10M-$23.02M
EBITDA-$64.20M———————
EPS (basic)-0.14-0.12-0.11—-0.24-0.31-0.26—
EPS (diluted)-0.14-0.12-0.11—-0.24-0.31-0.26—
Weighted avg. shares (diluted)451.03M433.54M428.30M—136.81M134.48M102.62M—
Balance sheet
Cash & equivalents$165.70M$174.90M$229.20M$194.20M$69.80M$103.20M$13.00M$32.50M
Current assets$189.60M$201.90M$246.70M$212.90M$88.88M$121.24M$29.15M$44.39M
PP&E, net$11.50M$9.70M$9.90M$10.40M$10.54M$11.05M$10.81M$11.31M
Intangibles——$100,000$0$21,000$26,000$29,000$40,000
Total assets$215.40M$223.20M$266.40M$233.70M$110.50M$143.43M$50.56M$65.66M
Current liabilities$58.50M$54.30M$51.80M$58.00M$49.48M$49.42M$40.38M$31.14M
Long-term debt$200,000——$0————
Total debt$200,000——$0————
Total liabilities$66.70M$62.80M$58.40M$64.90M$57.64M$57.20M$47.69M$38.27M
Shareholders' equity$148.60M$160.40M$207.90M$168.80M$52.90M$86.20M$2.90M$27.40M
Net debt-$165.50M——-$194.20M————
Shares outstanding————136.98M136.97M102.86M102.85M
Cash flow statement
Operating cash flow-$51.50M-$52.60M-$49.10M-$35.17M-$32.40M-$33.90M-$19.70M-$12.25M
Capital expenditure$2.20M$400,000$400,000$373,000$200,000$0$0-$125,000
Free cash flow-$53.70M-$53.00M-$49.50M-$35.55M-$32.60M-$33.90M-$19.70M-$12.13M
Investing cash flow-$5.30M-$600,000-$300,000-$715,000-$300,000$0-$400,000$793,000
Financing cash flow$48.10M$100,000$88.90M$159.06M$100,000$117.00M$0$675,000
Depreciation & amortization$600,000———————
Stock-based compensation$5.00M$3.70M$2.30M$1.92M$500,000$1.20M$1.70M-$453,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.